DNA Plasmids for Non-viral Gene Therapy of Cancer

Cancer Gene Therapy by Viral and Non-viral Vectors

Volumn , Issue , 2014, Pages 39-59

  Najjar, Amer M ^a   Moyes, Judy S E ^a   Cooper, Laurence J N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adoptive T cell therapy; Cytokines; DNA vaccines; Electroporation; Genomic integration; Hydrodynamic injection; Ischemia; Liposomes; Non viral gene delivery; Sonoporation; Transgene expression

Indexed keywords

EID: 84924790033     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118501665.ch3     Document Type: Chapter

References (157)

1. ClinicalTrials.gov. (2013) Bethesda: National Institutes of Health. http://clinicaltrials.gov/ct2/results?term=DNA&recr=Open.
2. Coster HG. (1965) A quantitative analysis of the voltage- current relationships of fixed charge membranes and the associated property of "punch-through". Biophysics Journal 5(5): 669-686.
3. Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. (1982) Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO Journal 1(7): 841-845.
4. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. (1990) Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1): 1465-1468.
5. Lin H, Parmacek MS, Morle G, Bolling S, Leiden JM. (1990) Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation 82(6): 2217-2221.
6. Yang JP, Huang L. (1996) Direct gene transfer to mouse melanoma by intratumor injection of free DNA. Gene Therapy 3(6): 542-548.
7. Jaroszeski MJ, Gilbert R, Nicolau C, Heller R. (1999) In vivo gene delivery by electroporation. Advanced Drug Delivery Reviews 35(1): 131-137.
8. Goldspink G. (2003) Skeletal muscle as an artificial endocrine tissue. Best Practice & Research Clinical Endocrinology & Metabolism 17(2): 211-222.
9. Zhang L, Li L, Hoffmann GA, Hoffman RM. (1996) Depth-targeted efficient gene delivery and expression in the skin by pulsed electric fields: an approach to gene therapy of skin aging and other diseases. Biochemical and Biophysical Research Communications 220(3): 633-636.
10. Rols MP. (2008) Mechanism by which electroporation mediates DNA migration and entry into cells and targeted tissues. Methods in Molecular Biology 423: 19-33.
11. Teissie J, Rols MP. (eds) (1992) Time Course of Electropermeabilization. Boston: Birkhauser Press.
12. Jaroszeski MJ, Gilbert R, Fallon PG, Heller R. (1994) Mechanically facilitated cell-cell electrofusion. Biophysics Journal 67(4): 1574-1581.
13. Pavlin M, Flisar K, Kanduser M. (2010) The role of electrophoresis in gene electrotransfer. Journal of Membrane Biology 236(1): 75-79.
14. Neumann E, Kakorin S, Toensing K. (1999) Fundamentals of electroporative delivery of drugs and genes. Bioelectrochemistry and Bioenergetics 48(1): 3-16.
15. Badding MA, Lapek JD, Friedman AE, Dean DA. (2013) Proteomic and functional analyses of protein-DNA complexes during gene transfer. Molecular Therapy 21(4): 775-785.
16. Gresch O, Engel FB, Nesic D, Tran TT, England HM, Hickman ES, et al. (2004) New non-viral method for gene transfer into primary cells. Methods 33(2): 151-163.
17. Zeitelhofer M, Vessey JP, Xie Y, Tubing F, Thomas S, Kiebler M, et al. (2007) High-efficiency transfection of mammalian neurons via nucleofection. Nature Protocols 2(7): 1692-1704.
18. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, et al. (2008) Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Research 68(8): 2961-2971.
19. Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, et al. (2013) Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells. PLoS One 8(5): e64138.
20. Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, et al. (2013) Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. Journal of Visualized Experiments 72: e50070.
21. Chopinet L, Wasungu L, Rols MP. (2012) First explanations for differences in electrotransfection efficiency in vitro and in vivo using spheroid model. International Journal of Pharmacy 423(1): 7-15.
22. Ribeiro S, Mairhofer J, Madeira C, Diogo MM, Lobato da Silva C, Monteiro G, et al. (2012) Plasmid DNA size does affect nonviral gene delivery efficiency in stem cells. Cellular Reprogramming 14(2): 130-137.
23. Tolmachov OE. (2010) Tightly-wound miniknot vectors for gene therapy: a potential improvement over supercoiled minicircle DNA. Medical Hypotheses 74(4): 702-704.
24. Heller R, Cruz Y, Heller LC, Gilbert RA, Jaroszeski MJ. (2010) Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array. Human Gene Therapy 21(3): 357-362.
25. Ferraro B, Heller LC, Cruz YL, Guo S, Donate A, Heller R. (2011) Evaluation of delivery conditions for cutaneous plasmid electrotransfer using a multielectrode array. Gene Therapy 18(5): 496-500.
26. Gothelf A, Hojman P, Gehl J. (2010) Therapeutic levels of erythropoietin (EPO) achieved after gene electrotransfer to skin in mice. Gene Therapy 17(9): 1077-1084.
27. Fear EC, Stuchly MA. (1998) Biological cells with gap junctions in low-frequency electric fields. IEEE Transactions on Biomedical Engineering 45(7): 856-866.
28. Molnar MJ, Gilbert R, Lu Y, Liu AB, Guo A, Larochelle N, et al. (2004) Factors influencing the efficacy, longevity, and safety of electroporation-assisted plasmid-based gene transfer into mouse muscles. Molecular Therapy 10(3): 447-455.
29. Lesbordes JC, Bordet T, Haase G, Castelnau-Ptakhine L, Rouhani S, Gilgenkrantz H, et al. (2002) In vivo electrotransfer of the cardiotrophin-1 gene into skeletal muscle slows down progression of motor neuron degeneration in pmn mice. Human Molecular Genetics 11(14): 1615-1625.
30. Terada Y, Tanaka H, Okado T, Inoshita S, Kuwahara M, Akiba T, et al. (2001) Efficient and ligand-dependent regulated erythropoietin production by naked dna injection and in vivo electroporation. American Journal of Kidney Diseases 38(4 Suppl 1): S50-S53.
31. Foster H, Sharp PS, Athanasopoulos T, Trollet C, Graham IR, Foster K, et al. (2008) Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Molecular Therapy 16(11): 1825-1832.
32. Gwon HC, Jeong JO, Kim HJ, Park SW, Lee SH, Park SJ, et al. (2001) The feasibility and safety of fluoroscopyguided percutaneous intramyocardial gene injection in porcine heart. International Journal of Cardiology 79(1): 77-88.
33. Miyahara T, Umeda Y, Yoshikawa S, Matsuno Y, Iwata H, Takemura H. (2012) Selective blockade of apoptosis by in vivo electroporation-mediated gene transfer combined with portal infusion of plasmid DNA attenuates liver cirrhosis. Minerva Chirurgica 67(3): 249-255.
34. Torrieri-Dramard L, Lambrecht B, Ferreira HL, Van den Berg T, Klatzmann D, Bellier B. (2011) Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Molecular Therapy 19(3): 602-611.
35. Budker V, Zhang G, Danko I, Williams P, Wolff J. (1998) The efficient expression of intravascularly delivered DNA in rat muscle. Gene Therapy 5(2): 272-276.
36. Liu F, Song Y, Liu D. (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Therapy 6(7): 1258-1266.
37. Hackett PB Jr, Aronovich EL, Hunter D, Urness M, Bell JB, Kass SJ, et al. (2011) Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer Delivery Systems in preclinical animal studies. Current Gene Therapy 11(5): 341-349.
38. Eastman SJ, Baskin KM, Hodges BL, Chu Q, Gates A, Dreusicke R, et al. (2002) Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA. Human Gene Therapy 13(17): 2065-2077.
39. Zhang G, Ludtke JJ, Thioudellet C, Kleinpeter P, Antoniou M, Herweijer H, et al. (2004) Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy. Human Gene Therapy 15(8): 770-782.
40. Chu Q, Joseph M, Przybylska M, Yew NS, Scheule RK. (2005) Transient siRNA-mediated attenuation of liver expression from an alpha-galactosidase A plasmid reduces subsequent humoral immune responses to the transgene product in mice. Molecular Therapy 12(2): 264-273.
41. Chen L, Woo SL. (2005) Complete and persistent phenotypic correction of phenylketonuria in mice by sitespecific genome integration of murine phenylalanine hydroxylase cDNA. Proceedings of the National Academy of Sciences USA 102(43): 15581-15586.
42. He CX, Shi D, Wu WJ, Ding YF, Feng DM, Lu B, et al. (2004) Insulin expression in livers of diabetic mice mediated by hydrodynamics-based administration. World Journal of Gastroenterology 10(4): 567-572.
43. Nejak-Bowen KN, Thompson MD, Singh S, Bowen WC Jr, Dar MJ, Khillan J, et al. (2010) Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. Hepatology 51(5): 1603-1613.
44. Crespo A, Peydro A, Dasi F, Benet M, Calvete JJ, Revert F, et al. (2005) Hydrodynamic liver gene transfer mechanism involves transient sinusoidal blood stasis and massive hepatocyte endocytic vesicles. Gene Therapy 12(11): 927-935.
45. Kobayashi N, Nishikawa M, Hirata K, Takakura Y. (2004) Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery. The Journal of Gene Medicine 6(5): 584-592.
46. Zhang G, Budker VG, Ludtke JJ, Wolff JA. (2004) Naked DNA gene transfer in mammalian cells. Methods in Molecular Biology 245: 251-264.
47. Smyth Templeton N. (2002) Liposomal delivery of nucleic acids in vivo. DNA and Cell Biology 21(12): 857-867.
48. Luo D, Saltzman WM. (2000) Synthetic DNA delivery systems. Nature Biotechnology 18(1): 33-37.
49. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. (1997) Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nature Biotechnology 15(7): 647-652.
50. Rodamporn S, Harris NR, Beeby SP, Boltryk RJ, Sanchez-Elsner T. (2011) HeLa cell transfection using a novel sonoporation system. IEEE Transactions on Biomedical Engineering 58(4): 927-934.
51. Taniyama Y, Tachibana K, Hiraoka K, Aoki M, Yamamoto S, Matsumoto K, et al. (2002) Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Therapy 9(6): 372-380.
52. Lawrie A, Brisken AF, Francis SE, Cumberland DC, Crossman DC, Newman CM. (2000) Microbubbleenhanced ultrasound for vascular gene delivery. Gene Therapy 7(23): 2023-2027.
53. Huang Q, Deng J, Xie Z, Wang F, Chen S, Lei B, et al. (2012) Effective gene transfer into central nervous system following ultrasound-microbubbles-induced opening of the blood-brain barrier. Ultrasound in Medicine and Biology 38(7): 1234-1243.
54. Shimamura M, Sato N, Taniyama Y, Kurinami H, Tanaka H, Takami T, et al. (2005) Gene transfer into adult rat spinal cord using naked plasmid DNA and ultrasound microbubbles. The Journal of Gene Medicine 7(11): 1468-1474.
55. Manome Y, Nakayama N, Nakayama K, Furuhata H. (2005) Insonation facilitates plasmid DNA transfection into the central nervous system and microbubbles enhance the effect. Ultrasound in Medicine and Biology 31(5): 693-702.
56. Phillips LC, Klibanov AL, Bowles DK, Ragosta M, Hossack JA, Wamhoff BR. (2010) Focused in vivo delivery of plasmid DNA to the porcine vascular wall via intravascular ultrasound destruction of microbubbles. Journal of Vascular Research 47(3): 270-274.
57. Casey G, Cashman JP, Morrissey D, Whelan MC, Larkin JO, Soden DM, et al. (2010) Sonoporation mediated immunogene therapy of solid tumors. Ultrasound in Medicine and Biology 36(3): 430-440.
58. Delalande A, Bouakaz A, Renault G, Tabareau F, Kotopoulis S, Midoux P, et al. (2011) Ultrasound and microbubble-assisted gene delivery in Achilles tendons: long lasting gene expression and restoration of fibromodulin KO phenotype. Journal of Controlled Release 156(2): 223-230.
59. Koike H, Tomita N, Azuma H, Taniyama Y, Yamasaki K, Kunugiza Y, et al. (2005) An efficient gene transfer method mediated by ultrasound and microbubbles into the kidney. The Journal of Gene Medicine 7(1): 108-116.
60. Sharei A, Zoldan J, Adamo A, Sim WY, Cho N, Jackson E, et al. (2013) A vector-free microfluidic platform for intracellular delivery. Proceedings of the National Academy of Sciences USA 110(6): 2082-2087.
61. Lee J, Sharei A, Sim WY, Adamo A, Langer R, Jensen KF, et al. (2012) Nonendocytic delivery of functional engineered nanoparticles into the cytoplasm of live cells using a novel, high-throughput microfluidic device. Nano Letters 12(12): 6322-6327.
62. Peng J, Zhao Y, Mai J, Guo W, Xu Y. Short noncoding DNA fragment improve efficiencies of in vivo electroporation- mediated gene transfer. Journal of Gene Medicine. 2012 Sep-Oct;14(9-10): 563-569.
63. Marie C, Vandermeulen G, Quiviger M, Richard M, Preat V, Scherman D. (2010) pFARs, plasmids free of antibiotic resistance markers, display high-level transgene expression in muscle, skin and tumour cells. The Journal of Gene Medicine 12(4): 323-332.
64. Herweijer H, Zhang G, Subbotin VM, Budker V, Williams P, Wolff JA. (2001) Time course of gene expression after plasmid DNA gene transfer to the liver. The Journal of Gene Medicine 3(3): 280-291.
65. Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, et al. (2010) Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Research 70(10): 3915-3924.
66. Blomberg P, Eskandarpour M, Xia S, Sylven C, Islam KB. (2002) Electroporation in combination with a plasmid vector containing SV40 enhancer elements results in increased and persistent gene expression in mouse muscle. Biochemical and Biophysical Research Communications 298(4): 505-510.
67. Gazdhar A, Bilici M, Pierog J, Ayuni EL, Gugger M, Wetterwald A, et al. (2006) In vivo electroporation and ubiquitin promoter-a protocol for sustained gene expression in the lung. The Journal of Gene Medicine 8(7): 910-918.
68. Luke JM, Vincent JM, Du SX, Gerdemann U, Leen AM, Whalen RG, et al. (2011) Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers. Gene Therapy 18(4): 334-343.
69. Hagedorn C, Wong SP, Harbottle R, Lipps HJ. (2011) Scaffold/matrix attached region-based nonviral episomal vectors. Human Gene Therapy 22(8): 915-923.
70. Narum DL, Kumar S, Rogers WO, Fuhrmann SR, Liang H, Oakley M, et al. (2001) Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infection & Immunity 69(12): 7250-7253.
71. Stratford R, Douce G, Zhang-Barber L, Fairweather N, Eskola J, Dougan G. (2000) Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus. Vaccine 19(7-8): 810-815.
72. Ramakrishna L, Anand KK, Mohankumar KM, Ranga U. (2004) Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. Journal of Virology 78(17): 9174-9189.
73. Megati S, Garcia-Hand D, Cappello S, Roopchand V, Masood A, Xu R, et al. (2008) Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cellmediated immune responses. Vaccine 26(40): 5083-5094.
74. Ternette N, Tippler B, Uberla K, Grunwald T. (2007) Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 25(41): 7271-7279.
75. Mossadegh N, Gissmann L, Muller M, Zentgraf H, Alonso A, Tomakidi P. (2004) Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology 326(1): 57-66.
76. Kosovac D, Wild J, Ludwig C, Meissner S, Bauer AP, Wagner R. (2011) Minimal doses of a sequenceoptimized transgene mediate high-level and long-term EPO expression in vivo: challenging CpG-free gene design. Gene Therapy 18(2): 189-198.
77. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, et al. (2003) T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101(4): 1637-1644.
78. Stoll SM, Sclimenti CR, Baba EJ, Meuse L, Kay MA, Calos MP. (2001) Epstein-Barr virus/human vector provides high-level, long-term expression of alpha1-antitrypsin in mice. Molecular Therapy 4(2): 122-129.
79. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, et al. (1996) Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273(5273): 352-354.
80. Stan AC, Casares S, Brumeanu TD, Klinman DM, Bona CA. (2001) CpG motifs of DNA vaccines induce the expression of chemokines and MHC class II molecules on myocytes. European Journal of Immunology 31(1): 301-310.
81. Bird AP. (1987) Cpg islands as gene markers in the vertebrate nucleus. Trends in Genetics 3(12): 342-347.
82. Reyes-Sandoval A, Ertl HC. (2004) CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses. Molecular Therapy 9(2): 249-261.
83. Mitsui M, Nishikawa M, Zang L, Ando M, Hattori K, Takahashi Y, et al. (2009) Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. The Journal of Gene Medicine 11(5): 435-443.
84. Chen ZY, He CY, Ehrhardt A, Kay MA. (2003) Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Molecular Therapy 8(3): 495-500.
85. Wicks IP, Howell ML, Hancock T, Kohsaka H, Olee T, Carson DA. (1995) Bacterial lipopolysaccharide copurifies with plasmid DNA: implications for animal models and human gene therapy. Human Gene Therapy 6(3): 317-323.
86. Firozi P, Zhang W, Chen L, Quiocho FA, Worley KC, Templeton NS. (2010) Identification and removal of colanic acid from plasmid DNA preparations: implications for gene therapy. Gene Therapy 17(12): 1484-1499.
87. Horn NA, Meek JA, Budahazi G, Marquet M. (1995) Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Human Gene Therapy 6(5): 565-573.
88. Kim JY, Cho C, Cho BN. (2010) Plasmid DNA of high quality purified by activated charcoal. Journal of Bioscience and Bioengineering 110(5): 608-613.
89. Wooddell CI, Subbotin VM, Sebestyen MG, Griffin JB, Zhang G, Schleef M, et al. (2011) Muscle damage after delivery of naked plasmid DNA into skeletal muscles is batch dependent. Human Gene Therapy 22(2): 225-235.
90. Dincer Z, Jones S, Haworth R. (2006) Preclinical safety assessment of a DNA vaccine using particle-mediated epidermal delivery in domestic pig, minipig and mouse. Experimental and Toxicologic Pathology 57(5-6): 351-357.
91. Hutnick NA, Myles DJ, Ferraro B, Lucke C, Lin F, Yan J, et al. (2012) Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. Human Gene Therapy 23(9): 943-950.
92. Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, et al. (2012) Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 7(1): e29231.
93. Wloch MK, Smith LR, Boutsaboualoy S, Reyes L, Han C, Kehler J, et al. (2008) Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. Journal of Infectious Disease 197(12): 1634-1642.
94. Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, et al. (2010) Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 28(13): 2565-2572.
95. Hegge JO, Wooddell CI, Zhang G, Hagstrom JE, Braun S, Huss T, et al. (2010) Evaluation of hydrodynamic limb vein injections in nonhuman primates. Human Gene Therapy 21(7): 829-842.
96. Henry TD, Hirsch AT, Goldman J, Wang YL, Lips DL, McMillan WD, et al. (2011) Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study. Gene Therapy 18(8): 788-794.
97. Thioudellet C, Blot S, Squiban P, Fardeau M, Braun S. (2002) Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part I: rationale. Neuromuscular Disorders 12(Suppl 1):S49-S51.
98. Romero NB, Benveniste O, Payan C, Braun S, Squiban P, Herson S, et al. (2002) Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part II: clinical protocol. Neuromuscular Disorders 12(Suppl 1):S45-S48.
99. Ayuni EL, Gazdhar A, Giraud MN, Kadner A, Gugger M, Cecchini M, et al. (2010) In vivo electroporation mediated gene delivery to the beating heart. PLoS One 5(12): e14467.
100. Kalil RA, Salles FB, Giusti II, Rodrigues CG, Han SW, Sant'Anna RT, et al. (2010) VEGF gene therapy for angiogenesis in refractory angina: phase I/II clinical trial. Revista Brasileira de Cirurgia Cardiovascular 25(3): 311-321.
101. Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, et al. (2010) piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Human Gene Therapy 21(4): 427-437.
102. Li X, Burnight ER, Cooney AL, Malani N, Brady T, Sander JD, et al. (2013) piggyBac transposase tools for genome engineering. Proceedings of the National Academy of Sciences USA 110(25): E2279-E2287.
103. Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. (2013) Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Translational Research 161(4): 265-283.
104. Hackett PB, Largaespada DA, Cooper LJ. (2010) A transposon and transposase system for human application. Molecular Therapy 18(4): 674-683.
105. Jin Z, Maiti S, Huls H, Singh H, Olivares S, Mates L, et al. (2011) The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Therapy 18(9): 849-856.
106. Durai S, Mani M, Kandavelou K, Wu J, Porteus MH, Chandrasegaran S. (2005) Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Research 33(18): 5978-5990.
107. Carlson DF, Fahrenkrug SC, Hackett PB. (2012) Targeting DNA with fingers and TALENs. Molecular Therapy Nucleic Acids 1: e3.
108. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121): 819-823.
109. Huang S, Kawabe Y, Ito A, Kamihira M. (2012) Adenoassociated virus Rep-mediated targeting of integrasedefective retroviral vector DNA circles into human chromosome 19. Biochemical and Biophysical Research Communications 417(1): 78-83.
110. Ginsburg DS, Calos MP. (2005) Site-specific integration with phiC31 integrase for prolonged expression of therapeutic genes. Advances in Genetics 54: 179-187.
111. Liu J, Skjorringe T, Gjetting T, Jensen TG. (2009) PhiC31 integrase induces a DNA damage response and chromosomal rearrangements in human adult fibroblasts. BMC Biotechnology 9: 31.
112. Cooper MJ, Lippa M, Payne JM, Hatzivassiliou G, Reifenberg E, Fayazi B, et al. (1997) Safety-modified episomal vectors for human gene therapy. Proceedings of the National Academy of Sciences USA 94(12): 6450-6455.
113. Holmstrom F, Pasetto A, Nahr V, Brass A, Kriegs M, Hildt E, et al. (2013) A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T Cell responses in wild-type and NS5A-transgenic mice. Journal of Immunology 190(3): 1113-1124.
114. Yamazaki T, Nagashima M, Ninomiya D, Arai Y, Teshima Y, Fujimoto A, et al. (2011) Passive immuneprophylaxis against influenza virus infection by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from plasmids. Japanese Journal of Infectious Disease 64(1): 40-49.
115. Ramanathan MP, Kutzler MA, Kuo YC, Yan J, Liu H, Shah V, et al. (2009) Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII. Vaccine 27(32): 4370-4380.
116. Hallengard D, Haller BK, Maltais AK, Gelius E, Nihlmark K, Wahren B, et al. (2011) Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation. Clinical and Vaccine Immunology 18(9): 1577-1581.
117. Chen Q, Kuang H, Wang H, Fang F, Yang Z, Zhang Z, et al. (2009) Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes 38(1): 30-38.
118. Xu K, Ling ZY, Sun L, Xu Y, Bian C, He Y, et al. (2011) Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunology 24(1): 45-56.
119. van Drunen Littel-van den Hurk S, Luxembourg A, Ellefsen B, Wilson D, Ubach A, Hannaman D, et al. (2008) Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle. Vaccine 26(43): 5503-5509.
120. Yin J, Dai A, Lecureux J, Arango T, Kutzler MA, Yan J, et al. (2011) High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine 29(39): 6763-6770.
121. Valentin A, von Gegerfelt A, Rosati M, Miteloudis G, Alicea C, Bergamaschi C, et al. (2010) Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine 28(8): 1962-1974.
122. Rosati M, Valentin A, Jalah R, Patel V, von Gegerfelt A, Bergamaschi C, et al. (2008) Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 26(40): 5223-5229.
123. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408(6813): 740-745.
124. Ma X, Forns X, Gutierrez R, Mushahwar IK, Wu T, Payette PJ, et al. (2002) DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine 20(27-28): 3263-3271.
125. Kojima Y, Xin KQ, Ooki T, Hamajima K, Oikawa T, Shinoda K, et al. (2002) Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 20(23-24): 2857-2865.
126. Verfaillie T, Cox E, Goddeeris BM. (2005) Immunostimulatory capacity of DNA vaccine vectors in porcine PBMC: a specific role for CpG-motifs? Veterinary Immunology and Immunopathology 103(1-2): 141-151.
127. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112(6): 2261-2271.
128. Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. (2010) Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biology of Blood and Marrow Transplantation 16(9): 1245-1256.
129. Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, et al. (2012) Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Human Gene Therapy 23(5): 444-450.
130. Cheng W, Miao L, Zhang H, Yang O, Ge H, Li Y, et al. (2013) Induction of interleukin 2 expression in the liver for the treatment of H22 hepatoma in mice. Digestive and Liver Disease 45(1): 50-57.
131. He X, Li W, Wang Y, Hou L, Zhu L. (2012) Inhibition of colon tumor growth by IL-15 immunogene therapy. Molecular Medicine Reports 5(1): 96-102.
132. Matsumoto K, Kikuchi E, Horinaga M, Takeda T, Miyajima A, Nakagawa K, et al. (2011) Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model. Human Gene Therapy 22(11): 1423-1432.
133. Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, et al. (2013) Antitumor immunotherapeutic and toxic properties of an HDLconjugated chimeric IL-15 fusion protein. Cancer Research 73(1): 139-149.
134. Yin X, Yan X, Yang Q, Cao H, Liang H. (2010) Antitumor mechanism of recombinant murine interleukin-12 vaccine. Cancer Biotherapy & Radiopharmaceuticals 25(3): 263-268.
135. Pavlin D, Cemazar M, Sersa G, Tozon N. (2012) IL-12 based gene therapy in veterinary medicine. J Translational Medicine 10: 234.
136. Cemazar M, Jarm T, Sersa G. (2010) Cancer electrogene therapy with interleukin-12. Current Gene Therapy 10(4): 300-311.
137. Zhu S, Lee DA, Li S. (2010) IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. Journal of Immunology 184(5): 2348-2354.
138. Rodriguez AM, Pascutti MF, Maeto C, Falivene J, Holgado MP, Turk G, et al. (2012) IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12_BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality. PLoS One 7(5): e37801.
139. Li S, Qi X, Gao Y, Hao Y, Cui L, Ruan L, et al. (2010) IL-15 increases the frequency of effector memory CD8+ T cells in rhesus monkeys immunized with HIV vaccine. Cellular and Molecular Immunology 7(6): 491-494.
140. Yoon WS, Choi HJ, Park YK. (2011) Salmonella typhimurium harboring plasmid expressing interleukin-12 induced attenuation of infection and protective immune responses. Journal of General and Applied Microbiology 57(2): 115-122.
141. Daugimont L, Vandermeulen G, Defresne F, Bouzin C, Mir LM, Bouquet C, et al. (2011) Antitumoral and antimetastatic effect of antiangiogenic plasmids in B16 melanoma: Higher efficiency of the recombinant disintegrin domain of ADAM 15. European Journal of Pharmaceutics and Biopharmaceutics 78(3): 314-319.
142. Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos AK, Quest AF, et al. (2010) Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunology Immunotherapy 59(1): 81-92.
143. Chan RC, Gutierrez B, Ichim TE, Lin F. (2009) Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous B16 melanoma. Oncology Reports 22(5): 1197-1203.
144. Johnen S, Izsvak Z, Stocker M, Harmening N, Salz AK, Walter P, et al. (2012) Sleeping Beauty transposonmediated transfection of retinal and iris pigment epithelial cells. Investigative Ophthalmology & Visual Science 53(8): 4787-4796.
145. Matsuda R, Kezuka T, Nishiyama C, Usui Y, Matsunaga Y, Okunuki Y, et al. (2012) Interleukin-10 genetransfected mature dendritic cells suppress murine experimental autoimmune optic neuritis. Investigative Ophthalmology & Visual Science 53(11): 7235-7245.
146. Fakin R, Hamacher J, Gugger M, Gazdhar A, Moser H, Schmid RA. (2011) Prolonged amelioration of acute lung allograft rejection by sequential overexpression of human interleukin-10 and hepatocyte growth factor in rats. Experimental Lung Research 37(9): 555-562.
147. Aistrup GL, Cokic I, Ng J, Gordon D, Koduri H, Browne S, et al. (2011) Targeted nonviral gene-based inhibition of Galpha(i/o)-mediated vagal signaling in the posterior left atrium decreases vagal-induced atrial fibrillation. Heart Rhythm 8(11): 1722-1729.
148. Penn MS, Mendelsohn FO, Schaer GL, Sherman W, Farr M, Pastore J, et al. (2013) An open-label dose escalation study to evaluate the safety of administration of non-viral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circulation Research 112(5): 816-825.
149. Marshall WG Jr, Boone BA, Burgos JD, Gografe SI, Baldwin MK, Danielson ML, et al. (2010) Electroporation-mediated delivery of a naked DNA plasmid expressing VEGF to the porcine heart enhances protein expression. Gene Therapy 17(3): 419-423.
150. Powell RJ, Goodney P, Mendelsohn FO, Moen EK, Annex BH. (2010) Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. Journal of Vascular Surgery 52(6): 1525-1530.
151. Shigematsu H, Yasuda K, Iwai T, Sasajima T, Ishimaru S, Ohashi Y, et al. (2010) Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Therapy 17(9): 1152-1161.
152. Morishita R, Aoki M, Hashiya N, Makino H, Yamasaki K, Azuma J, et al. (2004) Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44(2): 203-209.
153. Makarevich P, Tsokolaeva Z, Shevelev A, Rybalkin I, Shevchenko E, Beloglazova I, et al. (2012) Combined transfer of human VEGF165 and HGF genes renders potent angiogenic effect in ischemic skeletal muscle. PLoS One 7(6): e38776.
154. Nikol S, Baumgartner I, Van Belle E, Diehm C, Visona A, Capogrossi MC, et al. (2008) Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Molecular Therapy 16(5): 972-978.
155. Ferraro B, Cruz YL, Baldwin M, Coppola D, Heller R. (2010) Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation. Gene Therapy 17(6): 763-769.
156. Murakami T, Imada Y, Kawamura M, Takahashi T, Fujita Y, Sato E, et al. (2011) Placental growth factor-2 gene transfer by electroporation restores diabetic sensory neuropathy in mice. Experimental Neurology 227(1): 195-202.
157. Higuti E, Cecchi CR, Oliveira NA, Vieira DP, Jensen TG, Jorge AA, et al. (2012) Growth responses following a single intra-muscular hGH plasmid administration compared to daily injections of hGH in dwarf mice. Current Gene Therapy 12(6): 437-443.